Denver Solutions, LLC, dba Leiters Health, Englewood, CO
Is Denver Solutions, LLC, dba Leiters Health an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Denver Solutions, LLC, dba Leiters Health in Englewood, CO, first registered Mar 24, 2017 and most recently registered Oct 21, 2026. FDA lists its last inspection as Dec 11, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Untitled Letter Issued 6/8/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Englewood, CO
- Initial registration
- Mar 24, 2017
- Most recent registration
- Oct 21, 2026
- Last inspection
- Dec 11, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Untitled Letter Issued 6/8/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Denver Solutions, LLC (dba Leiter's Health), Englewood, CO, a 503B facility, with 8 listed actions, including 4 Form 483s and 1 untitled letter (2019 to 2026).
| Document | |||
|---|---|---|---|
| Jun 8, 2026 | Untitled letter | Untitled Letter Issued 06/08/2026 | fda.gov |
| Dec 11, 2025 | Form 483 | 483 Issued 12/11/2025 | fda.gov |
| Nov 20, 2024 | FMD-145 letter | FMD-145 Letter Issued 11/20/2024 | Not linked by FDA |
| Apr 5, 2024 | Form 483 | 483 Issued 04/05/2024 | FDA copy (archived) |
| Mar 29, 2022 | FMD-145 letter | FMD-145 Letter Issued 03/29/2022 | Not linked by FDA |
| Oct 7, 2021 | Form 483 | 483 Issued 10/07/2021 | fda.gov |
| May 26, 2021 | FMD-145 letter | FMD-145 Letter 05/26/2021 | Not linked by FDA |
| Jul 18, 2019 | Form 483 | 483 Issued 07/18/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Denver Solutions, LLC, Englewood, CO (FEI number 3013438582), matched to this page by exact name, city and state. It lists 5 inspections: 5 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Dec 11, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013438582 | 1294820 |
| Apr 5, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013438582 | 1235828 |
| Oct 7, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013438582 | 1153931 |
| Jul 18, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013438582 | 1096795 |
| Feb 23, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013438582 | 1042272 |
Form 483s FDA has published for this site
- Dec 11, 2025: Form 483 to Denver Solutions, LLC, published Jan 26, 2026. fda.gov
- Apr 5, 2024: Form 483 to Denver Solutions, LLC, published Jul 12, 2024. fda.gov
- Oct 7, 2021: Form 483 to Denver Solutions, LLC, published Feb 18, 2022. fda.gov
- Jul 18, 2019: Form 483 to Denver Solutions, LLC, published Sep 30, 2019. fda.gov
- Nov 15, 2018: Form 483 to Denver Solutions, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 19 numbered observations in all, across 4 inspections ending Feb 23, 2018 to Dec 11, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 13, 2025 to Dec 11, 2025: 7 observations
- Firm on the cover
- Denver Solutions, LLC, 13796 Compark Blvd, Englewood, CO 80112 -7145
- FEI number
- 3013438582
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
The aseptic filling process for Bevacizumab 25 mg/ml injection has not been adequately validated.
Specifically, the initial process validation was performed using a <Redacted B4> test method that your firm later determined was incapable of detecting the <Redacted B4>, particulates that are a known contaminant in your process. Furthermore, after making significant changes to the process-including the introduction of a new test method and the implementation of a critical <Redacted B4> step per SOP-0200 Avastin Processing Procedure <Redacted B4> you failed to perform a complete re-validation of the manufacturing process to demonstrate that it can consistently produce product meeting all specifications.
Since identifying <Redacted B4> contamination from your filling equipment, you have relied on <Redacted B4> as a routine manufacturing step to bring failing product back into specification. ...
Observation 2
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
Equipment used in the aseptic filling of Bevacizumab 25 mg/ml for intravitreal injection is not of appropriate design to prevent product contamination.
Specifically, your firm uses , as a product-contact component <Redacted B4> of your <Redacted B4>. Your investigation into Deviation <Redacted B4>. and a notebook study performed by your firm, confirmed that this leached <Redacted B4>, into the product, which is one of the main root causes of recurring Out-of-Specification (OOS) results for subvisible particulates. Despite this, you continue to use this component. The selection of this was not supported by initial qualification studies to ensure its suitability for use with a biologic product for ophthalmic use.
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, your firm has not developed an environmental monitoring plan based upon sound scientific methods to include appropriate sampling frequency and timing. Your firm has no documentation to demonstrate that the environmental sampling performed is representative of the entire process. For example,
a) Your firm <Redacted B4> active air samples per lot depending on fill time and shift changes. Your firm has no documented risk assessment to demonstrate that the sampling is representative of the entire filling process. For example,
• Lot #2530855 of Rocuronium Bromide 10mg/ml (5ml syringe) was filled on <Redacted B4> Filling started <Redacted B4> and ended at <Redacted B4>, Active air samples were taken at <Redacted B4>
• Lot #2530869 of Bupivacaine HCI 0.375% -Dexmethasone Sodium Phosphate 0.01 % -Epinephrine 1 :200,000 PF was filled on <Redacted B4> & <Redacted B4>. Filling started at and ended <Redacted B4> Active air samples were taken at <Redacted B4>
• Lot #2531047A of Dexmedetomidine HCI (20 mcg (base) per 5 ml) PF 5ml syringe was filled on <Redacted B4>. ...
Observation 4
Written procedures are not established that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.
Specifically, your firm has no documented justification for the sample size of <Redacted B4> matter the batch size or the extraction of only <Redacted B4> of solution from each of the <Redacted B4> containers to perform the supplemental visual inspection of drug products where the drug products and/or the container closure system permits limited visual inspection of the contents. For example, your firm fills Ropivacaine HCI 0.2% into opaque On-Q pumps (545ml and 745ml fills). Lot sizes since April 1, 2024 have ranged from <Redacted B4> pumps lots and sublets).
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically, your firm has no documentation to show the ISO <Redacted B4> area within the <Redacted B4> of the automated syringe filler (ASF in Room ) and the ISO laminar flow hoods where sterile drug products are filled into various types of containers (syringes, vials, dropper bottles, IV bags and On-Q pumps) have been certified under dynamic conditions. In addition, your firm has no documentation to demonstrate that the re-certification of the ISO <Redacted B4> and ISO <Redacted B4> cleanrooms were certified under dynamic conditions per ISO <Redacted B4> and including minimum number of sampling locations to be tested.
Observation 6
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
a) Disinfectant efficacy studies do not include all material from all critical areas where sterile drugs are made. For example,
• The studies failed to include the use of <Redacted B4> on any surface except for <Redacted B4> batches is used on surfaces in ISO cleanrooms/areas including equipment and laminar flow hoods.
• The studies failed to include the use of <Redacted B4> on all surfaces in the ISO <Redacted B4> areas for the automated syringe filler including the gloves and panels of the <Redacted B4> & <Redacted B4>
• The studies failed to include the materials that comprise the floors, walls and ceilings of the ISO <Redacted B4> and ISO <Redacted B4> cleanrooms.
b) On 11/13/2025, I observed rust and/or discoloration that appeared to be rust on the shelves of carts located in the ISO <Redacted B4> Cleanroom (Room ) where aseptic drug products are filled using an automated syringe filler within an ISO <Redacted B4>.
Observation 7
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
a) Your firm is taping shut media plates used for environmental and personnel monitoring (completely wrapping the plate closure) which may result in a low-oxygen environment inside the plates, which in turn could compromise the growth/recovery of aerobic microorganisms.
b) Your firm is not adequately preparing product samples for endotoxin testing. For example, your firm is not vortexing the product sample before removing the test portion for endotoxin testing.
Inspection dated Oct 7, 2021 by FDA (dates on the form not read): 7 observations
- Firm on the cover
- Denver Solutions, LLC DBA Leiters Health, 13796 Compark Blvd, Englewood, CO 80112-7145
- FEI number
- 3013438582
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6t h & Kipling St. (P.O. Box 25087) Denver, co 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed .
For example:
a) Visual inspection results of filled syringes were found to contain extraneous unidentified visible materials (particles and fibers) during 100% visual inspection processes, but no timely investigations were opened to identify the foreign materials, determine root cause as to how visible substances are found in a drug that is <Redacted B4> and containerized/filled in a HEPA filtered (ISO 5) environment, and prevent recurrence. For example, the following lots were found with some syringes containing foreign substances:
i) Lidocaine Lot <Redacted B4> found 30 syringes with particles and 1 syringe with a fiber manufactured in March 2021 .
ii) Phenylephrine Lot <Redacted B4> found 107 syringes containing particles and 17 syringes with fibers manufactured in February 2021.
iii) Fentanyl Citrate Lot <Redacted B4> found 20 syringes with particles and 25 syringes with fibers manufactured in January 2021. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
a) The Smoke Study performed for the [(o}(:21-) I (an open RABS) is not adequate to show all production areas have unidirectional airflow, as the Study shows detection of instances where there is turbulence.
i) The Smoke Study for the >J1;( shows that air (smoke) rises towards the ceiling in areas adjacent to the door that opens to the syringe bowl, and instead of air cascading towards the floor where uptakes are located, there
is turbulence instead of unidirectional airflow. Turbulence is indicated in this area (Starting at 2:18 in the 6Jl" Smoke Study) where ISO 5 air meets 150 7 air when this door is open, such as conducting set-up.
b) Disinfecting procedures (SOP 0090, Cleaning and Disinfection of ISO 7 and ISO 8 Areas and SOP 0088, Material Transfer) do not include an established contact time for <Redacted B4> in order to ensure disinfection. Procedures read that the application of <Redacted B4> should be "until dry" but this process gives varying time results, depending upon how much <Redacted B4> is applied. ...
Observation 3
Aseptic processing areas are deficient regarding air supply that is <Redacted B4> through high-efficiency <Redacted B4> to <Redacted B4> under positive pressure.
Specifically, ISO 5 hoods used for aseptic filling of compounded drug product are located in ISO 7 room ) <Redacted B4>. A review of alarms for differential pressure readings in room <Redacted B4> for the first six months of 2021 indicated 2,738 alarms reported. Of these alarm conditions, 58 days of commercial compounding show conditions of negative pressure into room <Redacted B4>. A total of <Redacted B4> commercial batches were filled on these 58 days. No investigations are performed when an alarm condition is recorded. No root cause for the condition is determined. No corrective action is taken to prevent reoccurrence.
Observation 4
Deviations from written production and process control procedures are not recorded.
Specifically,
a.) 00S 20007-DEN for potency of cyclopentolate/tropicamide/phenylephrine {CTP) batch <Redacted B4> was confirmed by the firm's contract laboratory. A root cause of a weighing error during production was determined. The firm did not complete a deviation investigation to determine corrective action.
b.) 00S 21004-DEN for potency of CTP batch <Redacted B4> was confirmed by the firm's contract laboratory. A root cause of a weighing error during production was determined. The firm did not complete a deviation investigation to determine corrective action.
Observation 5
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
a) During aseptic operations within the RABS of the <Redacted B4> line, in ISO 5, where sterilized syringes and caps are brought together, filled and sealed, there is an absence of continuous monitoring of viable air in the immediate proximity of exposed syringes and caps in a quantity and location intended to optimize detection of potential viable environmental contamination during aseptic operations. There is only one location where continuous viable air is monitored within <Redacted B4> of RABS space, which is a location where the filling operation is.
b) There is no viable air monitoring of aseptic setup operations in the ISO 5 <Redacted B4>.
Observation 6
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
When there is no scientific basis found for invalidating initial out-of-specification (OOS) test results and no assignable cause for the OOS is determined, procedures allow re-testing, which permits reporting additional analyses that meet specifications as the final result [SOP 0003, Out Of Specification Investigations, and per 2.1 of the procedure, "This procedure is applicable to OOS test results for any material or process controlled under specifications. This applies to release of raw materials, in-process, final product release, stability (including proposed shelf-life and accelerated studies), environmental and equipment OOS test results."] . Procedures in section 9.3.17 read in part, "If the preliminary investigation of the OOS result clearly demonstrates the result is attributable to indeterminate error, repeat the test (t5 (4) " And continues in section 9 .3 .18. ...
Observation 7
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, closures and labeling before disposition.
Specifically, on 09/23/2021 a portable cage marked "Rejected Materials" was observed to be unlocked and unattended. Several plastic bins were seen inside the cage with at least one containing compounded product.
Inspection Jul 1, 2019 to Jul 18, 2019: 1 observation
- Firm on the cover
- Denver Solutions, LLC DBA Leiter' s Health., 13796 Compark Blvd, Englewood, co 80112-714 5
- FEI number
- 3013438582
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipli ng St. (P. 0. Box 25 087 ) De nver, co 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient in that walls are not smooth and/or hard surfaces that are easily cleanable.
Specifically,
O n 7/1/19, I observed cracks and chips on the acrylic view screens of <Redacted B4> laminar flow hoods located in Room 195, where <Redacted B4> occurs. The crack in Hood <Redacted B4> appeared to be 5-inches in length spreading horizontally along the view screen above the sterile compounding work space. A thick and uneven bead of silicone caulk was used to repair the crack on an unknown date -there were no maintenance records for the repair. The crack and uneven caulk surface is not smooth or hard and therefore may be difficult to disinfect and sanitize.
In addition, your ISO 5 cleaning procedure (SOP 4.400 DEN) does not address cleaning the inside of the ac1ylic view screens and front surfaces, within the ISO 5 laminar air flow space where sterile air contacts and passes as it flows down to the compounding work space. On 7/8/19, I observed the ISO 5 laminar flow hood cleaning process and noted the inside of the front view screen and front surfaces were not cleaned prior to compounding. ...
Inspection Feb 12, 2018 to Feb 23, 2018: 4 observations
- Firm on the cover
- Denver Solutions, LLC DBA Leiter's Health, 13796 Compark Blvd, Englewood, CO 80112-7145
- FEI number
- 3013438582
- Establishment type on the cover
- out sourcing facility
- FDA district office on the cover
- 6th & Kipling St. (P.0. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Drug products failing to meet established quality control criteria are not rejected.
Specifically, on 02/14/18, I observed an unidentified black material imbedded into the wall of two filled syringes from Phenylephrine HCl injection, 100 mcg/mL, lot 1730021. The film's approved visual inspection process failed to detect the defects. One syringe was in the released inventory and the other was a reserve sample.
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
2A) On 02/14/18, I observed the QC Supervisor did not perform surface sampling of all equipment I observed used during production on 02/13/18. The QC supervisor failed to follow the approved sampling procedure and the procedure did not include adequate instuctions. Further questioning revealed the following:
Th e QC Supervisor confirmed the material cart I observed used to hold components prior to introduction into the ISO 5 hood does not get sampled. The material cart was moved throughout ISO 7 Room <Redacted B4> as needed during production.
T he QC Supervisor confirmed one of two tables in the middle of the room, which was used extensively throughout production, does not get sampled. I observed the table used to stage materials, write in logbooks, and other functions during production.
T he QC Supervisor confirmed there was no way to ensure all equipment in the ISO 7 room was sampled when there are multiple units, per the approved surface sampling procedure. ...
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Specifically, on 12/06/17, production personnel failed to perform the <Redacted B4> clean process for ISO 7 Rooms <Redacted B4> and <Redacted B4> after an extended loss of differential pressure. The walls, doors/ door frames, windows/ window frames, ceilings, and light fixtures were not disinfected per the approved procedure. Room <Redacted B4> is the <Redacted B4> where the ISO 5 hoods are located for aseptic processing operations. Operators moved materials through the improperly cleaned Room <Redacted B4> into Room <Redacted B4> to produce Phenylephrine HCl injection, 100 mcg/mL, lot 1730020 on 12/06/17.
Observation 4
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been aheady distributed.
Specifically, Operator performed aseptic filling for finished product lots 1730020, 1730021, 1830003, 1830015, 1830018, and 1830020 before he completed his gowning qualification on 02/13/18. No deviation was initiated per the approved procedure, and there was no assessment of the potential impact to the finished product lots.
Linked 483s whose text is not shown
- Apr 5, 2024: FDA document 180028: the FEI number and firm name on its cover do not match this page by the rule.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Denver Solutions, LLC, dba Leiters Health). That is not a finding beyond this index’s search.
The Denver Solutions, LLC, dba Leiters Health pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA’s 503B list also names Denver Solutions, LLC, dba Leiters Health, Buena, NJ. Each is a separate listing with its own records; a similar name does not show they are the same firm.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.